HIV-associated multicentric Castleman disease

Current Opinion in Oncology

Volumn 23, Issue 5, 2011, Pages 475-481

  Reddy, Deepa ^a   Mitsuyasu, Ronald ^b  

^a Division of Hematology Oncology   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Castleman; multicentric

Indexed keywords

ALPHA INTERFERON; BLEOMYCIN; CORTICOSTEROID; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GANCICLOVIR; INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; PREDNISONE; RITUXIMAB; TOCILIZUMAB; UNCLASSIFIED DRUG; VALGANGICLOVIR; VASCULOTROPIN; VINCRISTINE;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ARTICLE; CLINICAL FEATURE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; FOLLOW UP; HUMAN; HUMAN HERPESVIRUS 8; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROGNOSIS;

ADRENAL CORTEX HORMONES; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTINEOPLASTIC AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; DIAGNOSIS, DIFFERENTIAL; GIANT LYMPH NODE HYPERPLASIA; HERPESVIRIDAE INFECTIONS; HERPESVIRUS 8, HUMAN; HIV INFECTIONS; HUMANS; INTERLEUKIN-6;

EID: 80052033398     PISSN: 10408746     EISSN: 1531703X     Source Type: Journal    
DOI: 10.1097/CCO.0b013e328349c233     Document Type: Article

References (93)

1. Moore DF, Preti A, Tran SM. Prognostic implications following an indeterminate diagnostic work-up of lymphoma [abstract]. Blood 1996; 88 (Suppl 1): 229a.
2. Castleman B, Towne V. Case records of theMassachusetts General Hospital: case no. 40231. N Engl J Med 1954; 250:1001-1005.
3. Castleman B, Inverson L, Menedex V. Localized mediastinal lymph-node hyperplasia resembling thymoma. Cancer 1956; 9:822-830.
4. Festen C, Flendrig JA, Schillings PH. Giant lymphomas. Ned Tijdschr Geneeskd 1969; 113:1918-1919.
5. Menke DM, Tiemann M, Camoriano JK, et al. Diagnosis of Castleman's disease by identification of an immunophenotypically aberrant population of mantle zone B lymphocytes in paraffinembedded lymph node biopsies. Am J Clin Pathol 1996; 105:268-276. (Pubitemid 26077366)
6. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95:1406-1412. (Pubitemid 30099854)
7. Powles T, Stebbing J, Bazeos A, et al. The role of immune suppression and HHV-8 in the increasing incidence of HIV-associated multicentric Castleman's disease. Ann Oncol 2009; 20:775-779.
8. Lachant NA, Sun NC, Leong LA, et al. Multicentric angiofollicular lymph node hyperplasia (Castleman's disease) followed by Kaposi's sarcoma in two homosexual males with the acquired immunodeficiency syndrome (AIDS). Am J Clin Pathol 1985; 83:27-33. (Pubitemid 15159842)
9. Rywlin AM, Rosen L, Cabello B. Coexistence of Castleman's disease and Kaposi's sarcoma. Report of a case and a speculation. Am J Dermatopathol 1983; 5:277-281. (Pubitemid 13026074)
10. Chen KT. Multicentric Castleman's disease and Kaposi's sarcoma. Am J Surg Pathol 1984; 8:287-293. (Pubitemid 14126968)
11. Chang Y, Cesarman E, PessinMS, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma [see comments]. Science 1994; 266:1865-1869.
12. Moore PS, Chang Y. Detection of herpesvirus-like DNA sequences in Kaposi's sarcoma lesions from persons with and without HIV infection. New Engl J Med 1995; 332:1181-1185.
13. Buonaguro FM, Tornesello ML, Beth-Giraldo E, et al. Herpesvirus-like DNA sequences detected in endemic, classic, iatrogenic and epidemic Kaposi's sarcoma (KS) biopsies. Int J Cancer 1996; 65:25-28. (Pubitemid 26027535)
14. Cesarman E, Chang Y, Moore PS, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med 1995; 332:1186-1191.
15. Soulier J, Grollet L, Oskenhendler E, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood 1995; 86:1276-1280.
16. Suda T, Katano H, Delsol G, et al. HHV-8 infection status of AIDS-unrelated and AIDS-associated multicentric Castleman's disease. Pathol Int 2001; 51:671-679. (Pubitemid 32989612)
17. Izuchukwu IS, Tourbaf K, Mahoney MC. An unusual presentation of Castleman's disease: a case report. BMC Infect Dis 2003; 3:20.
18. Grandadam M, Dupin N, Calvez V, et al. Exacerbations of clinical symptoms in human immunodeficiency virus type 1-infected patients with multicentric Castleman's disease are associated with a high increase in Kaposi's sarcoma herpesvirus DNA load in peripheral blood mononuclear cells. J Infect Dis 1997; 175:1198-1201.
19. Bottieau E, Colebunders R, Schroyens W, et al. Multicentric Castleman's disease in 2 patients with HIV infection, unresponsive to antiviral therapy. Acta Clin Belg 2000; 55:97-101.
20. Oksenhendler E, CarcelainG, Aoki Y, et al. High levels of human herpesvirus 8 viral load, human interleukin-6, interleukin-10, and C reactive protein correlate with exacerbation of multicentric castleman disease in HIV-infected patients. Blood 2000; 96:2069-2073.
21. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473-3475.
22. Boivin G, Cote S, Cloutier N, et al. Quantification of human herpesvirus 8 by real-time PCR in blood fractions of AIDS patients with Kaposi's sarcoma and multicentric Castleman's disease. J Med Virol 2002; 68:399-403.
23. Berezne A, Agbalika F, Oksenhendler E. Failure of cidofovir in HIV-associated multicentric Castleman disease. Blood 2004; 103:4368-4369. (Pubitemid 38685387)
24. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIVassociated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-1634. (Pubitemid 38268952)
25. Katano H, Sato Y, Kurata T, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology 2000; 269:335-344. (Pubitemid 30210906)
26. Katano H, Sato Y, Itoh H, Sata T. Expression of human herpesvirus 8 (HHV-8)-encoded immediate early protein, open reading frame 50, in HHV-8-associated diseases. J Hum Virol 2001; 4:96-102. (Pubitemid 32574865)
27. Foss HD, Araujo I, Demel G, et al. Expression of vascular endothelial growth factor in lymphomas and Castleman's disease. J Pathol 1997; 183:44-50. (Pubitemid 27368525)
28. Nishi J, Arimura K, Utsunomiya A, et al. Expression of vascular endothelial growth factor in sera and lymph nodes of the plasma cell type of Castleman's disease. Br J Haematol 1999; 104:482-485. (Pubitemid 29119270)
29. Van Kooten C, Rensink I, Aarden L, van Oers R. Effect of IL-4 and IL-6 on the proliferation and differentiation of B-chronic lymphocytic leukemia cells. Leukemia 1993; 7:618-624. (Pubitemid 23139867)
30. Yoshizaki K, Matsuda T, Nishimoto N, et al. Pathogenic significance of interleukin-(IL-6/BSF-2) in Castleman's disease. Blood 1989; 74:1360-1367. (Pubitemid 19227448)
31. Brandt SJ, Bodine DM, Dunbar CE, Nienhuis AW. Dysregulated interleukin expression produces a syndrome resembling Castleman's disease in mice. J Clin Invest 1990; 86:592-599. (Pubitemid 20271895)
32. Beck JT, Hsu SM, Wijdenes J, et al. Brief report: alleviation of systemic manifestations of Castleman's disease by monoclonal antiinterleukin-6 antibody. New Eng J Med 1994; 330:602-605. (Pubitemid 24065794)
33. Nishimoto N, Sasai M, Shima Y, et al. Improvement in Castleman's disease by humanized antiinterleukin-6 receptor anti body therapy. Blood 2000; 95:56-61. (Pubitemid 30017224)
34. Molden J, Chang Y, You Y, et al. A Kaposi's sarcoma-associated herpesvirusencoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. J Biol Chem 1997; 272:19625-19631. (Pubitemid 27337768)
35. Osborne J, Moore PS, Chang Y. KSHV-encoded viral IL-6 activates multiple human IL-6 signaling pathways. Hum Immunol 1999; 60:921-927. (Pubitemid 29518115)
36. Mullberg J, Geib T, Jostock T, et al. IL-6 receptor independent stimulation of human gp130 by viral IL-6. J Immunol 2000; 164:4672-4677. (Pubitemid 30238067)
37. Li H, Wang H, Nicholas J. Detection of direct binding of human herpesvirus 8-encoded interleukin-6 (vIL-6) to both gp130 and IL-6 receptor (IL-6R) and identification of amino acid residues of vIL-6 important for IL-6R-dependent and-independent signaling. J Virol 2001; 75:3325-3334. (Pubitemid 32225895)
38. Boulanger MJ, Chow DC, Brevnova E, et al. Molecular mechanisms for viral mimicry of a human cytokine: activation of gp130 by HHV-8 interleukin-6. J Mol Biol 2004; 335:641-654. (Pubitemid 37532663)
39. Aoki Y, Jaffe ES, Chang Y, et al. Angiogenesis and hematopoiesis induced by Kaposi's sarcoma-associated herpesvirus-encoded interleukin-6. Blood 1999; 93:4034-4043. (Pubitemid 29279245)
40. Parravinci C, Corbellino M, Paulli M, et al. Expression of a virus-derived cytokine, KSHV vIL-6, in HIV-seronegative Castleman's disease. American Journal of Pathology 1997; 151:1517-1522. (Pubitemid 27527913)
41. MenkeDM, ChadbumA, Cesarman E, et al. Analysis of the human herpesvirus 8 (HHV-8) genome and HHV-8 vIL-6 expression in archival cases of castleman disease at low risk for HIV infection. Am J Clin Pathol 2002; 117:268-275. (Pubitemid 34823668)
42. Cannon JS, Nicholas J, Orenstein JM, et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis 1999; 180:824-828. (Pubitemid 29411370)
43. Aoki Y, Tosato G, Fonville TW, Pittaluga S. Serum viral interleukin-6 in AIDSrelated multicentric Castleman disease. Blood 2001; 97:2526-2527. (Pubitemid 32291504)
44. Casper C. The aetiology and management of Castleman disease at 50 years: translating pathophysiology to patient care. Br J Haematol 2005; 129:3-17. (Pubitemid 40524047)
45. Herrada J, Cabanillas F, Rice L, et al. The clinical behavior of localized and multicentric Castleman disease. Ann Intern Med 1998; 128:657-662. (Pubitemid 28169643)
46. Bowne WB, Lewis JJ, Filippa DA, et al. The management of unicentric and multicentric Castleman's disease: a report of 16 cases and a review of the literature. Cancer 1999; 85:706-717. (Pubitemid 29075292)
47. Chronowski GM, Ha CS, Wilder RB, et al. Treatment of unicentric and multicentric Castleman disease and the role of radiotherapy. Cancer 2001; 92:670-676. (Pubitemid 32735205)
48. Oksenhendler E, Duarte M, Soulier J, et al. Multicentric Castleman's disease in HIV infection: a clinical and pathological study of 20 patients. AIDS 1996; 10:61-67. (Pubitemid 26016404)
49. Van Rhee F, Stone K, Szmania S, et al. Castleman disease in the 21st century: an update on diagnosis, assessment, and therapy. Clin Adv Hematol Oncol 2010; 8:486-498.
50. Dham A, Peterson BA. Castleman disease. Curr Opin Hematol 2007; 14: 354-359. (Pubitemid 46842810)
51. Frizzera G, Peterson B, Bayrd E, et al. A systemic lymphoproliferative disorder with morphologic features of Castleman's disease: clinical findings and clinicopathologic correlations in 15 patients. J Clin Oncol 1985; 3:1202-1216. (Pubitemid 15226525)
52. Peterson BA, Frizzera G. Multicentric Castleman's disease. Semin Oncol 1993; 20:636-647. (Pubitemid 24015203)
53. Schmidt SM, Raible A, Kortum F, et al. Successful treatment of multicentric Castleman's disease with combined immunochemotherapy in an AIDS patient with multiorgan failure. Leukemia 2008; 22:1782-1785.
54. Hall PA, Donaghy M, Cotter FE, et al. An immunohistological and genotypic study of the plasma cell form of Castleman's disease. Histopathology 1989; 14:333-346; discussion 429-332. (Pubitemid 19129375)
55. Dupin N, Diss TL, Kellam P, et al. HHV-8 is associated with a plasmablastic variant of Castleman disease that is linked to HHV-8-positive plasmablastic lymphoma. Blood 2000; 95:1406-1412. (Pubitemid 30099854)
56. Dupin N, Fisher C, Kellam P, et al. Distribution of human herpesvirus-8 latently infected cells in Kaposi's sarcoma, multicentric Castleman's disease, and primary effusion lymphoma. Proc Natl Acad Sci USA 1999; 96:4546-4551. (Pubitemid 29190373)
57. Du MQ, Liu H, Diss TC, et al. Kaposi sarcoma-associated herpesvirus infects monotypic (IgM lambda) but polyclonal naive B cells in Castleman disease and associated lymphoproliferative disorders. Blood 2001; 97:2130-2136. (Pubitemid 32239096)
58. Judde JG, Lacoste V, Briere J, et al. Monoclonality or oligoclonality of human herpesvirus 8 terminal repeat sequences in Kaposi's sarcoma and other diseases. J Natl Cancer Inst 2000; 92:729-736. (Pubitemid 30365533)
59. Gerard L, Berezne A, Galicier L, et al. Prospective study of rituximab in chemotherapy-dependent human immunodeficiency virus associated multicentric Castleman's disease: ANRS 117 CastlemaB Trial. J Clin Oncol 2007; 25:3350-3356. (Pubitemid 47325622)
60. Scott D, Cabral L, Harrington W Jr. Treatment of HIV-associated multicentric Castleman's disease with oral etoposide. Am J Hematol 2001; 66:148-150. (Pubitemid 32096632)
61. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985; 16:162-172. (Pubitemid 15136927)
62. Bestawros A, Michel R, Seguin C, Routy JP. Multicentric Castleman's disease treated with combination chemotherapy and rituximab in four HIV positive men: a case series. Am J Hematol 2008; 83:508-511. (Pubitemid 351742803)
63. Oksenhendler E. HIV-associated multicentric Castleman disease. Curr Opin HIV AIDS 2009; 4:16-21.
64. Bower M. How I treat HIV-associated multicentric Castleman Disease. Blood 2010; 116:4415-4421.
65. Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized antiinterleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood 2005; 106:2627-2632. (Pubitemid 41510733)
66. Van Rhee F, Fayad L, Voorhees P, et al. Siltuximab, a novel anti-interleukin-6 monoclonal antibody, for Castleman's disease. J Clin Oncol 2010 [Epub ahead of print] This article reports the interim results of a phase I study evaluating the use of siltuximab in patients with CD.
67. Marcelin A, Aaron L, Mateus C, et al. Rituximab therapy for HIV-associated Castleman disease. Blood 2003; 102:2786-2788. (Pubitemid 37248847)
68. Bower M, Powles T, Williams S, et al. Brief communication: rituximab in HIVassociated multicentric Castleman disease. Ann Intern Med 2007; 147:836-839. (Pubitemid 351664423)
69. Neuville S, Agbalika F, Rabian C, et al. Failure of rituximab in human immunodeficiency virus-associated multicentric Castleman disease. Am J Hematol 2005; 79:337-339. (Pubitemid 41098853)
70. Buchler T, Dubash S, Lee V, et al. Rituximab failure in fulminant multicentric HIV/human herpesvirus 8-associated Castleman's disease with multiorgan failure: report of two cases. AIDS 2008; 22:1685-1687.
71. Powles T, Stebbing J, Montoto S, et al. Rituximab as retreatment for rituximab pretreated HIV-associated multicentric Castleman disease. Blood 2007; 110:4132-4133. (Pubitemid 350248476)
72. Michot JM,Gerard L, Burcheri S, et al. Impact of rituximab on incidence ofNHLin patients with HIV-associated MCD. CROI 2011; Session 23:abstract 83.
73. Hoffmann C, Muller M, Schmid H, et al. Improved outcome in patients with HIV-associated multicentric Castleman's disease during recent years: an effect of rituximab? CROI 2011; Session 26:abstract 861.
74. Weisenburger DD, Nathwani BN, Winberg CD, Rappaport H. Multicentric angiofollicular lymph node hyperplasia: a clinicopathologic study of 16 cases. Hum Pathol 1985; 16:162-172. (Pubitemid 15136927)
75. Kumari P, Schechter GP, Saini N, Benator DA. Successful treatment of human immunodeficiency virus-related Castleman's disease with interferonalpha. Clin Infect Dis 2000; 31:602-604. (Pubitemid 32289598)
76. Nord JA, Karter D. Low dose interferon-alpha therapy for HIV-associated multicentric Castleman's disease. Int J STD AIDS 2003; 14:61-62. (Pubitemid 36126995)
77. Jung CP, Emmerich B, Goebel FD, Bogner JR. Successful treatment of a patient with HIV-associated multicentric Castleman disease (MCD) with thalidomide. Am J Hematol 2004; 75:176-177. (Pubitemid 38263829)
78. Lee FC, Merchant SH. Alleviation of systemic manifestations of multicentric Castleman's disease by thalidomide. Am J Hematol 2003; 73:48-53. (Pubitemid 36504579)
79. Klass CM, Offermann MK. Targeting human herpesvirus-8 for treatment of Kaposi's sarcoma and primary effusion lymphoma. Curr Opin Oncol 2005; 17:447-455. (Pubitemid 41224925)
80. Corbellino M, Bestetti G, Scalamogna C, et al. Long-term remission of Kaposi sarcoma-associated herpesvirus-related multicentric Castleman disease with anti-CD20 monoclonal antibody therapy. Blood 2001; 98: 3473-3475.
81. Senanayake S, Kelly J, Lloyd A, et al. Multicentric Castleman's disease treated with antivirals and immunosuppressants. J Med Virol 2003; 71:399-403. (Pubitemid 37176629)
82. Revuelta MP, Nord JA. Successful treatment of multicentric Castleman's disease in a patient with human immunodeficiency virus infection. Clin Infect Dis 1998; 26:527. (Pubitemid 28083991)
83. Casper C, Nichols WG, Huang ML, et al. Remission of HHV-8 and HIVassociated multicentric Castleman disease with ganciclovir treatment. Blood 2004; 103:1632-1634. (Pubitemid 38268952)
84. Mylona EE, Baraboutis IG, Lekakis LJ, et al. Multicentric Castleman's disease in HIV infection: a systematic review of the literature. AIDS Rev 2008; 10:25-35. (Pubitemid 351524049)
85. Dupin N, Krivine A, Calvez V, et al. No effect of protease inhibitor on clinical and virological evolution of Castleman's disease in an HIV-1-infected patient. AIDS 1997; 11:1400-1401. (Pubitemid 27423306)
86. Zietz C, Bogner JR, Goebel FD, Lohrs U. An unusual cluster of cases of Castleman's disease during highly active antiretroviral therapy for AIDS. N Engl J Med 1999; 340:1923-1924. (Pubitemid 29272678)
87. Aaron L, Lidove O, Yousry C, et al. Human herpesvirus 8-positive Castleman disease in human immunodeficiency virus-infected patients: the impact of highly active antiretroviral therapy. Clin Infect Dis 2002; 35:880-882.
88. Sprinz E, Jeffman M, Liedke P, et al. Successful treatment of AIDS-related Castleman's disease following the administration of highly active antiretroviral therapy (HAART). Ann Oncol 2004; 15:356-358. (Pubitemid 38262642)
89. Lee SM, Edwards SG, Chilton DN, et al. Highly active antiretroviral therapy alone may be an effective treatment for HIV-associated multicentric Castleman's disease. Haematologica 2010; 95:1979-1981.
90. Loi S, Goldstein D, Clezy K, et al. Castleman's disease and HIV infection in Australia. HIV Med 2004; 5:157-162. (Pubitemid 38765282)
91. Oksenhendler E, Boulanger E, Galicier L, et al. High incidence of Kaposi sarcoma-associated herpesvirus-related non-Hodgkin lymphoma in patients with HIV infection and multicentric Castleman disease. Blood 2002; 99: 2331-2336. (Pubitemid 34525417)
92. Barker R, Kazmi F, Stebbing J, et al. FDG-PET/CT imaging in the management of HIV-associated multicentric Castleman's disease. Eur J Nucl Med Mol Imaging 2009; 36:648-652.
93. Polizzotto M, Millo C, Uldrick T, et al. 18-flouro-D-deoxyglucose PET in the diagnosis and monitoring of KSHV-MCD: correlation with clinical, inflammatory and virologic parameters. CROI 2011:abstract 862.